Drug launch prices rise significantly outpacing inflation and GDP growth: ICER
Source: SeekingAlpha
2025-10-23 12:19:26 ET
More on Bristol-Myers Squibb, Johnson & Johnson, etc.
- The Play On Bristol-Myers Squibb
- Merck: Earnings Outlook Steady, Keytruda Now Has Some Breathing Room
- Merck: A Golden Buying Opportunity
- Merck Keytruda formulations undergo FDA priority review for bladder cancer
- Goldman Sachs rebalances dividend yields & growth equity basket as earnings season begins
Read the full article on Seeking Alpha
For further details see:
Drug launch prices rise significantly outpacing inflation and GDP growth: ICER
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-0.86% G/L:
$68.375 Last:
674,082 Volume:
$68.81 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
